SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

HPPD

VTVT·vTv Therapeutics Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical
Time to market
Years away from potential commercialization if development proceeds. The drug is still preclinical with no IND filed; typical timelines from preclinical to approval in sickle cell disease are 5-10 years, assuming successful clinical development.
Why 2/10
HPPD is a preclinical program with no hard dated catalyst in the next ~12 months. The company's value is overwhelmingly driven by its lead asset cadisegliatin (Phase 3 CATT1 topline readout expected mid-2027). HPPD is a small, early-stage pipeline component that adds optionality but cannot drive a significant share-price move on its own in the near term.
Actionable Insight NEUTRAL

HPPD has no hard dated catalyst in the next ~12 months; the next major binary event for vTv Therapeutics is the Phase 3 CATT1 topline readout for cadisegliatin expected mid-2027. Any partnership deal for HPPD could provide a non-dilutive cash infusion and serve as a positive catalyst, but is not guaranteed. Watch for IND filing announcements or partnership news as the next potential HPPD-specific catalysts.

Price Chart

Loading chart...

Executive Summary

HPPD (HPP8668) is vTv Therapeutics' preclinical, oral, first-in-class Nrf2/Bach1 modulator being developed for sickle cell disease. It received FDA Orphan Drug Designation in October 2026 based on preclinical data in the Townes mouse model showing fetal hemoglobin induction comparable to or exceeding hydroxyurea. However, HPPD remains at the preclinical stage with no IND filed and no human data. The company's primary focus and cash resources are directed toward its lead asset cadisegliatin (Phase 3 for type 1 diabetes, topline mid-2027). vTv is positioning HPPD for partnering discussions rather than internal advancement. For a non-medical investor, HPPD is an early-stage pipeline asset that adds optionality but is not a near-term value driver for the stock.

How It Works

HPPD is an oral drug that modulates two cellular pathways (Nrf2 and Bach1) to increase production of fetal hemoglobin, a type of hemoglobin that is naturally present at birth but declines after infancy. In sickle cell disease, fetal hemoglobin can prevent the abnormal sickling of red blood cells that causes pain and organ damage. By boosting fetal hemoglobin levels, HPPD aims to reduce the symptoms of sickle cell disease. This is similar in concept to hydroxyurea (the current standard of care) but works through a different mechanism.

Trial Status

HPPD is in preclinical development. Studies have been conducted in the Townes sickle cell disease mouse model showing time- and dose-dependent fetal hemoglobin induction. No IND has been filed and no human clinical trials have been initiated. The company is pursuing partnering discussions for HPPD while prioritizing its lead cadisegliatin program.

The Two-Sided Case

▲ Bull Case5
First-in-class oral Nrf2/Bach1 modulator with a novel mechanism for sickle cell disease, distinct from gene therapies and hydroxyurea
FDA Orphan Drug Designation provides 7-year market exclusivity if approved, plus tax credits and fee waivers, and signals regulatory interest
Preclinical data showed fetal hemoglobin induction comparable to or exceeding hydroxyurea, the current standard of care
Company is actively pursuing partnering discussions for HPPD, which could bring non-dilutive funding and validate the asset
Strong analyst consensus with 12 Buy/Strong Buy ratings and a mean price target of $56 (166% upside from $21.03)
▼ Bear Case5
HPPD is still preclinical with no IND filed and no human data; most preclinical drug candidates never reach the market
The company's primary focus and $77.2M cash runway are allocated to the cadisegliatin Phase 3 trial, not HPPD advancement
Sickle cell disease has multiple approved treatments including gene therapies (Casgevy, Lyfgenia) and hydroxyurea, creating a competitive landscape
Stock has fallen from a 52-week high of $44 to $21.03, reflecting market skepticism about the broader pipeline
Zero revenue and a quarterly cash burn of ~$11.6M may require additional financing before the cadisegliatin readout in mid-2027

Upcoming Catalysts

  • Potential partnership/licensing deal for HPPD (no timeline given)
  • Possible IND filing (no date announced)
  • Phase 3 CATT1 topline data for cadisegliatin (mid 2027) - the company's primary value driver

Source Filing

The SecBot filing or press-release report that triggered this drug report:

vTv Therapeutics Inc. PRESS-RELEASE VTVT ·Originating report

Sources · 8

Hover a chip for the title
1 morningstar.com2 streetinsider.com3 bioworld.com4 msn.com5 streetinsider.com6 markets.businessinsider.com7 streetinsider.com8 marketwatch.com